Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2022 - 03 - 29 save search
Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy Commercial launch expected in 2Q 2022
Published: 2022-03-29 (Crawled : 21:00) - biospace.com/
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.48%
H: 0.87%
C: -1.45%
treatment fda pharma approval therapy commercialization
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
Published: 2022-03-29 (Crawled : 18:00) - biospace.com/
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: -1.87%
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
fda approval hiv order
First FDA-Approved Molecular Targeted Therapy for Metastatic Prostate Cancer Now Available at Hoag Family Cancer Institute
Published: 2022-03-29 (Crawled : 18:00) - prnewswire.com
FNCTF | News | $11.16 1.13% -20.84% 0
|
Communications
| Email alert
Add to watchlist
therapy molecular cancer fda prostate cancer
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
Published: 2022-03-29 (Crawled : 13:00) - biospace.com/
URGN | $14.21 -2.2% -2.04% 97K
|
Health Technology
|
| O: -0.67%
H: 10.08%
C: 7.95%
ugn-301 fda clearance application immunotherapy cancer bladder
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™
Published: 2022-03-29 (Crawled : 13:00) - biospace.com/
LPCN | $4.44 -7.5% -6.43% 66K
|
Health Technology
|
| O: -16.48%
H: 7.89%
C: -4.61%
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.48%
H: 0.87%
C: -1.45%
fda approval
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
Published: 2022-03-29 (Crawled : 12:00) - biospace.com/
ENTA | $12.92 -1.75% -1.9% 90K
|
Health Technology
|
| O: 2.11%
H: 4.37%
C: 1.23%
edp-235 covid-19 treatment fda fast track designation designation
Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis
Published: 2022-03-29 (Crawled : 12:00) - biospace.com/
OCUP | News | $1.53 -0.65% -1.32% 90K
|
Health Technology
|
| O: -12.82%
H: 7.96%
C: -3.91%
nyxol fda trial positive results topline phase 3
Envista Obtains FDA Clearance for Assisted Intelligence Mandibular Nerve Tracing
Published: 2022-03-29 (Crawled : 02:00) - prnewswire.com
NVST | $20.28 0.3% 0.0% 1.2M
|
Health Technology
|
| O: 0.67%
H: 2.22%
C: -3.54%
fda clearance trace
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 17M
|
TSLA | News | $162.13 12.06% 10.13% 170M
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.